Due to the negative prognostic impact, it is important to accurately detect undiagnosed glucose perturbations in patients with acute coronary syndromes (ACS). Design: This study compares oral glucose tolerance test (OGTT) to fasting plasma glucose (FPG) and HbA1c as screening tools.
Methods:
Patients hospitalized for ACS had an OGTT, FPG, and HbA1c measured 4–21 (median 6) days after admission as a screening process for an intervention study.
Results:
Out of 174 patients, 75 (43%) had a normal glucose tolerance, 63 (36%) impaired glucose tolerance (IGT), and 36 (21%) diabetes type 2 (T2DM). Of these, 20 were non-eligible, and of the remaining 79 patients, 52 had IGT and 27 T2DM according to the OGTT. In patients with IGT, the median FPG was 6.0 mmol/l and the median HbA1c was 39 mmol/mol. The corresponding levels in patients with T2DM were 6.3 mmol/l and 41 mmol/mol, respectively. Seventeen of the 27 patients with T2DM according to OGTT had not been disclosed if the screening had been based on FPG. HbA1c identified two patients.
Conclusions:
Compared to OGTT, the use of FPG or HbA1c alone leaves a majority of patients with IGT or T2DM undetected when screening for unknown glucose perturbations as a part of total risk assessment of patients with ACS.
NorhammarATenerzANilssonG. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet2002; 359: 2140–2144.
2.
BartnikMRydénLFerrariR. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J2004; 25: 1880–1890.
3.
HuDYPanCYYuJM. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart J2006; 27: 2573–2579.
4.
TamitaKKatayamaMTakagiT. Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circ J2007; 71: 834–841.
5.
BartnikMMalmbergKNorhammarA. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J2004; 25: 1990–1997.
6.
GrahamIAtarDBorch-JohnsenK. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil2007; 14 Suppl 2: E1–E40.
7.
RydénLStandlEBartnikM. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J2007; 28: 88–136.
8.
BartnikMRydenLMalmbergK. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart2007; 93: 72–77.
9.
World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation. Geneva: WHO, 2011.
10.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2010; 33 Suppl 1: S62–S69.
11.
Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502–1513.
12.
World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: WHO, 2006.
13.
PeterAFritscheAStefanN. Diagnostic value of hemoglobin A1c for type 2 diabetes mellitus in a population at risk. Exp Clin Endocrinol Diabetes2011; 119: 234–237.
14.
van 't RietEAlssemaMRijkelijkhuizenJM. Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. Diabetes Care2010; 33: 61–66.
15.
SinnaevePRStegPGFoxKA. Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Arch Intern Med2009; 169: 402–409.
16.
de MulderMOemrawsinghRMStamF. Comparison of diagnostic criteria to detect undiagnosed diabetes in hyperglycaemic patients with acute coronary syndrome. Heart2012; 98: 37–41.
17.
DoerrRHoffmannUOtterW. Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography: the Silent Diabetes Study. Diabetologia2011; 54: 2923–2930.
18.
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet1999; 354: 617–621.
19.
DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med2001; 161: 397–405.
20.
NakagamiT. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia2004; 47: 385–394.
TuomilehtoJLindstromJErikssonJG. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001; 344: 1343–1350.
23.
KnowlerWCBarrett-ConnorEFowlerSE. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002; 346: 393–403.
24.
CoutinhoMGersteinHCWangY. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care1999; 22: 233–240.
25.
AnselminoMOhrvikJMalmbergK. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J2008; 29: 177–184.
26.
ChiassonJLJosseRGGomisR. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet2002; 359: 2072–2077.
27.
WallanderMMalmbergKNorhammarA. Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study. Diabetes Care2008; 31: 36–38.
